They suggest that SF3B1 is a promising novel druggable target as well as a prognostic biomarker in HCC [51], as has been reported in other malignancies, such as pancreas [52], breast [53], and prostate [54] cancers. This evidence concerns the gene SF3B1 and hepatocellular carcinoma.